

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and *PCT International Application*	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.11.2003)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	United States Patent and Trademark Office (USPTO) (RO/US)
0-7	Applicant's or agent's file reference	PU4964WO
I	Title of invention	CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	SMITHKLINE BEECHAM CORPORATION
II-5	Address:	One Franklin Plaza Philadelphia, PA 19101 United States of America
II-6	State of nationality	US
II-7	State of residence	US
II-8	Telephone No.	919-483-2370
II-9	Facsimile No.	919-483-7988
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	PECKHAM, Jennifer, Poole
III-1-5	Address:	GlaxoSmithKline Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709 United States of America
III-1-6	State of nationality	US
III-1-7	State of residence	US

III-2	<b>Applicant and/or inventor</b>	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	AQUINO, Christopher, Joseph
III-2-5	Address:	GlaxoSmithKline Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709 United States of America
III-2-6	State of nationality	US
III-2-7	State of residence	US
III-3	<b>Applicant and/or inventor</b>	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	KAZMIERSKI, Wieslaw, Mieczyslaw
III-3-5	Address:	GlaxoSmithKline Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709 United States of America
III-3-6	State of nationality	US
III-3-7	State of residence	US
IV-1	<b>Agent or common representative; or address for correspondence</b> The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	LEVY, David, J
IV-1-2	Address:	GlaxoSmithKline Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709 United States of America
IV-1-3	Telephone No.	919-483-2370
IV-1-4	Facsimile No.	919-483-7988
IV-2	<b>Additional agent(s)</b>	additional agent(s) with same address as first named agent
IV-2-1	Name(s)	DEPPENBROCK, Bonnie, L

<b>V</b>	<b>Designation of States</b>	
<b>V-1</b>	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p><b>AP:</b> BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p><b>EA:</b> AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p><b>EP:</b> AT BE BG CH&amp;LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p><b>OA:</b> BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>
<b>V-2</b>	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p><b>AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH&amp;LI CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW</b></p>
<b>V-5</b>	<b>Precautionary Designation Statement</b>  In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
<b>V-6</b>	<b>Exclusion(s) from precautionary designations</b>	<b>NONE</b>
<b>VI-1</b>	<b>Priority claim of earlier national application</b>	
VI-1-1	Filing date	<b>13 December 2002 (13.12.2002)</b>
VI-1-2	Number	<b>60/433,626</b>
VI-1-3	Country	<b>US</b>

VI-2	<b>Priority document request</b> The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	<b>VI-1</b>	
VII-1	<b>International Searching Authority Chosen</b>	<b>European Patent Office (EPO) (ISA/EP)</b>	
VIII	<b>Declarations</b>	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	<b>Check list</b>	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	5	-
IX-2	Description	101	-
IX-3	Claims	36	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	0	-
IX-7	TOTAL	143	
	<b>Accompanying items</b>	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-11	Copy of general power of attorney	reference no. SB Corp	-
IX-12	Statement explaining lack of signature	✓	-
IX-17	PCT-EASY diskette	-	Diskette
IX-18	Other (specified):	Copy of POA authorizing D. Levy signature for SB Corp	-
IX-19	Figure of the drawings which should accompany the abstract		
IX-20	Language of filing of the international application	English	
X-1	Signature of applicant, agent or common representative	<i>Bonnie L. Deppenbrock</i>	
X-1-1	Name (LAST, First)	DEPPENBROCK, Bonnie, L	

## FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

## FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--